✦ LIBER ✦

Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers

✍ Scribed by Annick Wong Wong Keet; Munir Al-Rafae; Pierre O. Chappuis; Jean-Sébastien Brunet; Parviz Ghadirian; William D. Foulkes

Publisher: John Wiley and Sons
Year: 2009
Tongue: French
Weight: 55 KB
Volume: 125
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.24596

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy of taxane chemotherapy for

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Mieke Kriege; Agnes Jager; Maartje J. Hooning; Elisabeth Huijskens; Jannet Blom; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 824 KB

Adjuvant systemic therapy for breast can

Adjuvant systemic therapy for breast cancer inBRCA1/BRCA2mutation carriers in a population-based study of risk of contralateral breast cancer

✍ Kerryn W. Reding; Jonine L. Bernstein; Bryan M. Langholz; Leslie Bernstein; Robe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 188 KB

Association between patient reported out

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

✍ Dawn L. Hershman; Louis H. Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; D 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 378 KB

BRCA1/2mutation testing in breast cancer

BRCA1/2mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy

✍ Kathryn J. Schlich-Bakker; Margreet G. E. M. Ausems; Maria Schipper; Herman F. J 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 260 KB

Relationship between oestrogen receptor

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

✍ Robin L. Jones; Janine Salter; Roger A’Hern; Ash Nerurkar; Marina Parton; Jorge 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 180 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views